CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Reyon Pharmaceutical Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Reyon Pharmaceutical Co Ltd
12F, A Dong, Mirae Asset Tower,
620, Teheran-ro, Gangnam-gu
Phone: +82 27935557p:+82 27935557 SEOUL, 06174  South Korea Ticker: 102460102460
Business Summary
Reyon Pharmaceutical Co Ltd is a Korea-based company primarily engaged in the manufacturing and sale of pharmaceuticals. The Company is mainly involved in the manufacturing and sale of prescription drugs, including cardiovascular drugs, antibiotics, eye drops, digestive system drugs, and anti-inflammatory drugs, as well as original drugs such as contrast agents, and active pharmaceutical ingredients. The Company also engages in new technology development and research services, design, equipment operation, maintenance, and sales of pharmaceutical plants, and investment, management, as well as operation of new technology-related businesses and startup support. The Company also operates in the new technology business financing business.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research
8711 Engineering services
8748 Business consulting services, not elsewhere classified
6799 Investors, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman, Co-Chief Executive Officer Sun OkJung 72 1/1/2021 1/17/2014
President, Co-Chief Executive Officer, Director Yong HwanYoo 48 1/1/2021 1/1/2021
Senior Vice President Jong HyeonPark 58 1/1/2021
10 additional Officers and Directors records available in full report.

General Information
Number of Employees: 455 (As of 9/30/2024)
Outstanding Shares: 18,340,991 (As of 9/30/2025)
Shareholders: 23,643
Stock Exchange: KRX
Fax Number: +82 27987538


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, February 3, 2026